Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Pancreatic Cancer and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3433
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Pancreatic Cancer and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Pancreatic Cancer and Cancer Vaccines.

    To find out more about Triple Analysis: Lung Cancer, Pancreatic Cancer and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Pancreatic Cancer and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
A&G Pharmaceutical
AB Science
Abbott
AC Immune
Active Biotech
Adaptimmune
Adherex
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Agennix
Agenus
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
AlphaVax
Altor BioScience
Amgen
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Ardea Biosciences
Argos Therapeutics
Ariad
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
AstraZeneca
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Benitec
Betapharma
Biogen Idec
Biokine Therapeutics
BioLineRx
Bionovo
BioNTech
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
CanBas
Cancer Advances
Cancer Research Technology
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chong Kun Dang
Circadian Technologies
Clavis Pharma
CLL Pharma
CompleGen
Cornerstone Pharmaceuticals
Coronado Biosciences
Cosmo Pharmaceuticals
CreaGene
Critical Outcome Technologies
CritiTech
CSL
Curaxis
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
DeveloGen
Dong-A
ECI
EGEN Inc
Eisai
Elara Pharmaceuticals
Eli Lilly
Endocyte
EntreMed
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Etubics
Exelixis
FibroGen
Fresenius
Galapagos
Galectin Therapeutics
Galena Biopharma
Gemin X Biotechnologies
Generex
Genmab
GenOdyssee Pharmaceuticals
Genta
Genticel
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Gradalis
Hanmi
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
immatics biotechnologies
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inovio
Insmed
Insys Therapeutics
Intezyne Technologies
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
Kiadis
Kyowa Hakko Kirin
Leo
Ligand
Lipotek
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Momotaro-Gene
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novogen
Oasmia
OncoGenex Pharmaceuticals
OncoMed
OncoMune
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
Pfizer
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Pro-Pharmaceuticals
Progen Pharmaceuticals
Progenics Pharmaceuticals
ProMetic Life Sciences
Protgen
Protherics
Radient Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
responsif
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
Scancell
Seattle Genetics
ShimodaAtlantic Oncology
Shionogi
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
SRI International
SuperGen
Supratek Pharma
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
UMN Pharma
United Biomedical
Vaccinex
Valeant
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
Vectura
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Virionics
ViroMed
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zensun
Zeria
Zhejiang Beta Pharma
Zivena
Zydus Cadila
A Shortlist of Drugs Included are:
abagovomab
ADXS11-001
AE-37
AEG-35156
afatinib
aflibercept
AGS-003
AGS-1C4D4
amrubicin hydrochloride
ANZ-207
apricoxib
ARC-100
ARQ-197
astuprotimut-r
Auto TAG vaccine
AVX-701
bardoxolone methyl
belagenpumatucel-L
belotecan hydrochloride
bevacizumab
BIBF-1120
bosutinib
BP-GMAX-CD1
brivanib alaninate
brivudine
BV-NSCLC-001
Cabozantinib
canfosfamide hydrochloride
capecitabine
catumaxomab
CB-10-01
CDX-1307
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
CPI-613
CreaVax-PC
crizotinib
CRLX-101
CV-9103
CV-9201
CVac
dacomitinib
dalotuzumab
dasatinib
DCVax-prostate
docetaxel
doxorubicin
E-75
E-7820
emepepimut-S
endostatin
eniluracil
enzastaurin hydrochloride
erlotinib
etoposide (1)
etoposide phosphate
everolimus
ganitumab
gefitinib
GI-4000
GSK-1120212
GSK-2130579A
GV-1001
GVAX
GVX-3322
Her-2/Neu peptides
Hi-8 MEL
HS-110
icotinib hydrochloride
ICT-107
imatinib mesilate
imMucin
IMO-2055
IMP-321
iniparib
interferon (gamma1b)
interleukin-12
ipilimumab
irinotecan
irinotecan hydrochloride
ISA-P53-01
JX-594
KD032
L19-IL2
lapatinib ditosylate
lestaurtinib
LipoVIL12
masitinib
MDX-1379
MetXia
MGN-1601
MKC-1
mocetinostat
motesanib diphosphate
motexafin gadolinium
MVA-BN Her-2 vaccine
nadroparin
necitumumab
nimotuzumab
oblimersen sodium
olaparib
OncoVAX
Onyvax-105
OTS-102
P-276-00
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
paclitaxel polyglumex
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
PX-12
ramucirumab
Reximmune-C
Rexin-G
rindopepimut
rintatolimod
romidepsin
RX-0201
S-488410
SCIB-1
selumetinib
siltuximab
sipuleucel-T
sorafenib tosylate
ß-lapachone
sunitinib malate
Survivac
talactoferrin alfa
talminogene laherparepvec
tegafur + uracil
temsirolimus
TG-4010
thymalfasin
tigatuzumab
tipapkinogene sovacivec
tocilizumab
topotecan
trabedersen
trastuzumab
triciribine phosphate
TroVax
TS-1
tucotuzumab celmoleukin
varlitinib
velimogene aliplasmid
verpasep caltespen
vismodegib
vitespen
volociximab
VX-001
WX-671
Z-360

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Pancreatic Cancer and Cancer Vaccines.
    To find out more about Triple Analysis: Lung Cancer, Pancreatic Cancer and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Pancreatic Cancer and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Leukemia and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Leukemia, Pancreatic Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Melanoma and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Leukemia, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Learn More